top of page

ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs

ACTION-1 ALPHA PRRT - Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy


CLINICALTRIALS.GOV IDENTIFIER: NCT05477576


DRUG/TREATMENT: ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection


COMPARED TO: Everolimus, Sunitinib, Octreotide, Lanreotide


PHASE: Phase 3


STATUS: Recruiting April 2023


SPONSOR: RayzeBio, Inc.


Dr. Heloisa Soares discusses the ACTION-1 Trial


Dr. Will Pegna discusses the ACTION-1 Trial Starting at 5:07



DESCRIPTION:

RayzeBio is sponsoring the ACTION-1 study, a phase 3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC.


Update - Aug 22, 2023


2023 ESMO Abstract shows preliminary safety and efficacy

(Note: The meaning of efficacy in clinical trials refers to the capacity of a treatment, device, or medication, to produce a desired effect on the patient population.)



Download the PDF here:

1198P-RYZ101-301-ESMO-2023-poster-UPLOAD
.pdf
Download PDF • 4.57MB

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.


CONTACT:

RayzeBio Clinical Trials

EMAIL: clinicaltrials@rayzebio.com

PHONE: 619-657-0057


bottom of page